文献速递消化系统肿瘤

围手术期化疗治疗可切除胰腺腺癌的2期随机临床试验

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项2期随机试验在可切除胰腺导管腺癌患者中比较围手术期mFOLFIRINOX与吉西他滨/白蛋白紫杉醇,主要终点为2年总生存率。在102例可评估患者中,两臂2年OS分别为47%和48%,均未显著高于预设40%阈值,未显示优于历史辅助治疗数据。

要点

  • 围手术期化疗两臂2年OS均未超过预设40%阈值。
  • mFOLFIRINOX与吉西他滨/白蛋白紫杉醇2年OS分别为47%和48%。
  • 中央影像复审发现29%患者疾病超出可切除标准。

核心结论

  • 围手术期化疗未较历史辅助治疗数据改善可切除胰腺癌总生存。
  • 两臂2年OS估计值均未显著高于预设40%阈值。

研究设计与样本

  • 随机2期试验,采用pick-the-winner设计,在全美国家临床试验网络开展。
  • 计划入组150例以计入中央影像复审不合格者,实际入组147例,可评估102例。
  • 入组标准为Zubrod体能评分0或1、组织学确诊胰腺导管腺癌、符合Intergroup可切除标准。

主要发现

  • mFOLFIRINOX臂2年OS为47%(95%CI 31%-61%),中位OS 23.2个月(95%CI 17.6-45.9个月)。
  • 吉西他滨/白蛋白紫杉醇臂2年OS为48%(95%CI 31%-63%),中位OS 23.6个月(95%CI 17.8-31.7个月)。
  • 两臂分别有73%和70%患者接受切除,切除后中位无病生存分别为10.9个月和14.2个月。
  • 不良事件为预期的血液学毒性、乏力和胃肠道毒性。

关键数值与推荐

  • 围手术期化疗为术前12周、术后12周。
  • mFOLFIRINOX臂完成术前化疗84%、完成全部治疗49%;吉西他滨/白蛋白紫杉醇臂分别为85%和40%。

临床怎么用

  • 围手术期化疗安全性可接受且切除率较高,但未显示生存优于辅助治疗历史数据。
  • 可切除性判定需中央影像质量控制,本试验29%患者复审超出可切除标准。

局限性

  • 为2期随机试验,样本量有限,结论需3期试验验证。
  • 采用pick-the-winner设计并与历史辅助治疗数据比较,非直接头对头比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial. OBJECTIVE: To determine 2-year overall survival (OS) using perioperative chemotherapy for resectable PDA. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized phase 2 trial of perioperative chemotherapy with a pick-the-winner design. It was conducted across the National Clinical Trials Network, including academic and community centers all across the US. Eligibility required patients with Zubrod Performance Score of 0 or 1, confirmed tissue diagnosis of PDA, and resectable disease per Intergroup criteria. INTERVENTIONS: Perioperative (12 weeks preoperative, 12 weeks postoperative) chemotherapy with either fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX, arm 1) or gemcitabine/nab-paclitaxel (arm 2). MAIN OUTCOMES AND MEASURES: The primary outcome was 2-year overall survival (OS), using a pick-the-winner design; for 100 eligible patients, accrual up to 150 patients was planned to account for cases deemed ineligible at central radiology review. RESULTS: From 2015 to 2018, 147 patients were enrolled; 43 patients (29%) had ineligible disease, beyond resectability criteria, at central radiology review. There were 102 eligible and evaluable patients, 55 in arm 1 and 47 in arm 2, of whom the median (range) age was 66 (44-76) and 64 (46-76) years, respectively; 36 patients (65%) in arm 1 and 24 (51%) in arm 2 were men. In arm 1, 34 (62%) had Zubrod Performance Score of 0, while in arm 2, 31 (66%) did; and 44 (80%) in arm 1 and 39 (83%) in arm 2 had head tumors. Of 102 patients, 84% and 85% completed preoperative chemotherapy, 73% and 70% underwent resection, and 49% and 40% completed all treatment. Adverse events were expected hematologic toxic effects, fatigue, and gastrointestinal toxicities. Two-year OS was 47% (95% CI, 31%-61%) for arm 1 and 48% (95% CI, 31%-63%) for arm 2; median OS was 23.2 months (95% CI, 17.6-45.9 months) and 23.6 months (95% CI, 17.8-31.7 months). Neither arm's 2-year OS estimate was significantly higher than the a priori threshold of 40%. Median disease-free survival after resection was 10.9 months in arm 1 and 14.2 months in arm 2. CONCLUSIONS AND RELEVANCE: This phase 2 randomized clinical trial did not demonstrate an improved OS with perioperative chemotherapy, compared with historical data from adjuvant trials in resectable pancreatic cancer. Two-year OS was 47% with mFOLFIRINOX and 48% with gemcitabine/nab-paclitaxel for all eligible patients starting treatment for resectable PDA. The trial also demonstrated adequate safety and high resectability rates with perioperative chemotherapy, and challenges in quality control for resectability criteria. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02562716.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33475684. doi:10.1001/jamaoncol.2020.7328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。